A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency

Trial Profile

A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2014

At a glance

  • Drugs Anacetrapib (Primary)
  • Indications Atherosclerosis; Coronary disorders; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa
  • Focus Pharmacokinetics
  • Sponsors Merck & Co
  • Most Recent Events

    • 12 May 2014 New trial record
    • 01 May 2014 Results published in the Journal of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top